Recently, two genomic amplifications on chromosome 12 have been observed, involving the mapping sites of MDM2, CDK4, and FRS2 genes, and these aberrations were correlated with NB patients’ poor clinical outcome [81]. The gene discussed is MDM2; the disease is neuroblastoma.